Based on our previous findings that the super‐enhancer‐targeting drug JQ1 can inhibit KLF5 transcription and its potential therapeutic effect in ovarian cancer, as well as its role in enhancing PARPi sensitivity, we propose that a combination treatment of JQ1 and olaparib can be considered for OC patients with super‐enhancer‐driven KLF5 and concurrent PARPi resistance. This evidence concerns the gene KLF5 and ovarian carcinoma.